Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials

Recombinant factor VIII (rFVIII) products provide a safe and efficacious replacement therapy for prevention and treatment of bleeding episodes in patients with haemophilia A. The present investigations from the multinational, open-label guardian™ clinical trials assessed the haemostatic response of...

Descripción completa

Detalles Bibliográficos
Autores principales: Santagostino, E, Lentz, S R, Misgav, M, Brand, B, Chowdary, P, Savic, A, Kilinc, Y, Amit, Y, Amendola, A, Solimeno, L P, Saugstrup, T, Matytsina, I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2015
Materias:
Original Article Clinical haemophilia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309503/
https://www.ncbi.nlm.nih.gov/pubmed/25273984
http://dx.doi.org/10.1111/hae.12518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309503/
https://www.ncbi.nlm.nih.gov/pubmed/25273984
http://dx.doi.org/10.1111/hae.12518

Ejemplares similares